A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Diabinese
Synonyms :
chlorpropamide
Class :
Antidiabetics, Sulfonylureas
Brand Name :
Diabinese
Synonyms :
chlorpropamide
Class :
Antidiabetics, Sulfonylureas
Dosage forms & Strengths:Â
Adult:Â
Tablet
100 mg
250 mg
Safety and efficacy are not seen in pediatrics
Tablet
100 mg
250 mg
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
may have an increased risk of hypoglycemia when combined with chlorpropamide
may increase the therapeutic efficacy of each other when combined
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
meningococcal A C Y and W-135 diphtheria conjugate vaccine
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
CYP3A strong enhancers of the small intestine may reduce the bioavailability of chlorpropamide enzal
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may enhance the anticoagulant effect
may enhance the anticoagulant effect
may enhance the anticoagulant effect
may enhance the anticoagulant effect
may enhance the anticoagulant effect
chlorpropamide: they may enhance the serum concentration of urinary acidifying agents
chlorpropamide: they may enhance the serum concentration of urinary acidifying agents
chlorpropamide: they may enhance the serum concentration of urinary acidifying agents
Combining chlorpropamide with pranlukast may cause a reduction in the chlorpropamide’s metabolism
chlorpropamide has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
When helometasone is used together with chlorpropamide, this leads to elevated risk or seriousness of hyperglycemia
chlorpropamide leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
chlorpropamide leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
chlorpropamide leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
chlorpropamide may decrease the excretion rate of almasilate, leading to higher serum levels
When chlorpropamide is used together with diazoxide, this leads to reduction in therapeutic effectiveness of chlorpropamide
methylprednisolone hemisuccinateÂ
When methylprednisolone hemisuccinate is aided with chlorpropamide, this leads to elevated hyperglycemia risk
when both drugs are combined, there may be a decreased level of serum concentration of chlorpropamide    
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
they decrease the efficacy of antidiabetic agents
they decrease the efficacy of antidiabetic agents
they decrease the efficacy of antidiabetic agents
they decrease the efficacy of antidiabetic agents
may decrease the therapeutic effect of hyperglycemia agents
may enhance the serum concentration of CYP2C9 inhibitors
may increase the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
It may intensify the hypoglycemic effect of sulfonylureas
It has the potential to amplify the hypoglycemic impact of sulfonylureas
It may enhance the effect when combined with lixisenatide by pharmacodynamic synergism
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
lansoprazole, amoxicillin, and clarithromycin
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
bismuth subcitrate, metronidazole and tetracycline
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
the protein binding efficiency of chlorpropamide may be reduced when taken with mofebutazone
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
the toxicity of either of the drugs is increased due to pharmacokinetic synergism
may have a decrease in excretion when combined with chlorpropamide
the risk of hyperglycemia may be increased
the anti-diabetic efficacy of chlorpropamide can be reduced with mometasone furoate
chlorpropamide might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
the hypoglycemic activity of chlorpropamide may be increased
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of sulfonylureas
dipeptidyl peptidase-IV inhibitors increase the effect of hypoglycemia of sulfonylureas
when both drugs are combined, there may be an increased risk of adverse effects  
may enhance the effect of the other by cationic drug competition for renal tubular clearance
Actions and Spectrum:
The action of chlorpropamide inhibits the secretion of the alpha-glucosidase enzyme in the small intestine’s brush border. By inhibiting alpha-glucosidase, chlorpropamide slows the absorption of carbohydrates from the gut. It leads to a reduction in postprandial hyperglycemia.
Frequency Not Defined:
Hypoglycemia
Headache
Dizziness
Anorexia
Liver failure
Aplastic anemia
Nausea
Vomiting
Disulfiram-reactions
Blood dyscrasias
Dermatologic reactions
Black Box Warning:
It is essential to follow the dosage and administration instructions for the medication carefully.
Contraindication/Caution:
Patients with type 1 diabetes show contraindications for chlorpropamide. It is also contraindicated in patients with severe renal or hepatic impairment, as these patients may be at increased risk for adverse effects from the drug.
chlorpropamide should be used with caution in elderly patients.
Pregnancy consideration:
Category C.
Breastfeeding warnings:
The excretion of the drug in breast milk is unknown.
Pregnancy category:
Category A: well-controlled and Satisfactory studies do not show risk to the fetus in the first/later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology
chlorpropamide is a sulfonylurea antidiabetic drug. It is used to lower blood sugar levels in people with type 2 diabetes. It is a first-generation sulfonylurea. It has been used for an extended period and is generally less potent than newer second-generation sulfonylureas. Such as glipizide and glimepiride.
Pharmacodynamics:
It stimulates the release of insulin from the pancreas, which reduces blood glucose levels. Chlorpropamide also increases insulin sensitivity and slows glucose absorption from the gastrointestinal tract. Its effects last for approximately 24 hours.
Pharmacokinetics:
Pharmacokinetics studies how a drug is absorbed, distributed, metabolized, and eliminated by the body. The following parameters can describe the pharmacokinetics of chlorpropamide.
Absorption
chlorpropamide is well absorbed after oral administration and reaches maximum plasma concentrations within 2-4 hours.
Distribution
chlorpropamide has a low protein binding affinity and is widely distributed in the body. Metabolism
It is metabolized in the liver by CYP2C9 and has a half-life of approximately 40 hours.
Elimination and excretion
The drug is excreted in the urine, primarily as its metabolites.
Administration:
chlorpropamide is administered orally, typically taken as a tablet, once daily with a meal. The dosage is adjusted based on the patient’s blood glucose levels and response to treatment.
It is essential to monitor blood glucose regularly and adjust the dose as necessary to prevent hypoglycemia. Following a balanced diet and regular exercise while taking chlorpropamide is also essential.
Patient information leaflet
Generic Name: chlorpropamide.
Pronounced: klor-proe-pa-mide
Why do we use chlorpropamide?
chlorpropamide is used to treat type 2 diabetes.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
